Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Significance: Targeting more than one molecular cause implied in the pathogenesis of Alzheimer’s disease (AD) with a sole drug is considered a promising challenge, because it may address the numerous failures that recently occurred during clinical trials that were conducted in this area. Donecopride has been designed by us as a multitarget-directed ligand, targeting both serotonin subtype 4 receptor and acetylcholinesterase with excellent in vitro activities. The latter seems able to not only restore the cholinergic neurotransmission altered in AD but also, promote the secretion of a neurotrophic protein that is detrimental to the neurotoxic amyloid-β peptide. With its excellent drugability, donecopride further displayed significant procognitive effects in mice and generated a promising lead for a previously unidentified approach in AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377
PAMPA—critical factors for better predictions of absorption
Avdeef, A., Bendels, S., Di, L. I., Faller, B., Kansy, M., Sugano, K., & Yamauchi, Y. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21068 · Cited by 240
An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223 · cited 1×
“Considering that chronic treatments with RS67333 have already shown their ability to slow down AD pathology and prevent cognitive deficits in mice (36), donecopride opens the door to a previously unidentified class of compounds that could take advantage of the well-known properties of AChE inhibitors, and it could als…”
BackgroundSerotonin 5-HT2a and 5-HT2c Receptors Stimulate Amyloid Precursor Protein Ectodomain Secretion
Nitsch, R. M., Deng, M., Growdon, J. H., & Wurtman, R. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4188 · Cited by 219 · cited 1×
“However, activation of 5-HTR (5-HT2A, 5-HT2C, and 5-HT4) has been shown to also induce an increase in soluble form of APPα (34, 36, 43).”
BackgroundEglen, R. M., Bonhaus, D. W., Johnson, L. G., Leung, E., & Clark, R. D. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb16628.x · Cited by 102 · cited 5×
“Psychopharmacology (Berl) 202(1-3):125–139.”
BackgroundMethodInfluential
Cited by
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationAlbertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Self-citationMultitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Więckowska, A., Kołaczkowski, M., Bucki, A., Godyń, J., Marcinkowska, M., Więckowski, K., Zaręba, P., Siwek, A., Kazek, G., Głuch-Lutwin, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.016 · Cited by 91
Metadata
- Authors
- Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., Mignani, S., Cresteil, T., Boulouard, M., Claeysen, S., Rochais, C., & Dallemagne, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-08-25
- Volume
- 111
- Issue
- 36
- Pages
- E3825-30
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2013121971
- Cited by
- 133
- References
- 6
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. https://app.cochat.ai/papers/10.1073/pnas.1410315111
- The paper
- Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., Mignani, S., Cresteil, T., Boulouard, M., Claeysen, S., Rochais, C., & Dallemagne, P. (2014). Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1410315111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.